OFEV is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
OFEV is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).